Would you give adjuvant immunotherapy after nephrectomy?
Is DFS benefit in KN-564 in ASCO2021 sufficient evidence to change practice?
Community PollStarted
Will you give adjuvant pembrolizumab to patients with high risk RCC after nephrectomy?
30 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Vanderbilt-Ingram Cancer Center
Answered on
The KN-564 will certainly change the landscape of adjuvant RCC. Prior studies had either been negative, or have been positive (sunitinib in S-TRAC) but with toxicity that has precluded widespread use. The OS data from KN-564 is too immature to interpret, in my opinion, so the debate of whether to tr...
Join for free or sign in to see the full answer